Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How big is the parkinson’s disease market today, and what are its future growth expectations?
The parkinson’s disease market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing research and development, growth in government funding, growth in personalized treatment plans, growth in support networks for Parkinson’s disease patients, and increasing use of advanced rehabilitation therapies.
The parkinson’s disease market size is expected to see strong growth in the next few years. It will grow to $4.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising awareness about parkinson’s disease symptoms, rising government initiatives, increasing healthcare spending, a rising number of Parkinson’s disease clinical trials, and rising adoption of gene therapies. Major trends in the forecast period include technological advancements, government initiatives and funding, artificial intelligence in diagnosis, innovative solutions, and personalized medicine.
Get Your Free Sample of The Global Parkinson’s Disease Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp
What have been the primary factors driving the parkinson’s disease market’s growth?
Increasing prevalence of neurodegenerative diseases is expected to propel the growth of the parkinson’s disease market going forward. Neurodegenerative diseases refer to a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. The prevalence of neurodegenerative diseases is increasing due to factors such as an aging population, genetic predisposition, environmental influences, improved diagnosis, rising chronic health conditions, and lifestyle changes. Parkinson’s disease helps advance the understanding of neurodegenerative diseases by providing critical insights into their underlying mechanisms, potential therapeutic targets, and the development of innovative treatment approaches. For instance, in April 2022, according to the European Brain Council, a Belgium-based non-profit organization, over 600 neurological diseases and nearly 300 psychiatric conditions afflict millions globally, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Therefore, the increasing prevalence of neurodegenerative diseases is driving the growth of the parkinson’s disease market.
What are the key segments within the parkinson’s disease market?
The parkinson’s disease market covered in this report is segmented –
1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes
2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Route Of Administrations
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Patient Care Setting: Clinics, Hospitals
Subsegments:
1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives
2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone
3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine
5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations
6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report
Which key players are shaping the parkinson’s disease market?
Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.
How will emerging trends drive the parkinson’s disease market throughout the forecast period?
Major companies operating in the parkinson’s disease market are focusing on developing innovative solutions, such as levodopa-based therapy, to improve motor function and provide continuous symptom management for patients with advanced parkinson’s disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to enhance motor function and alleviate symptoms of Parkinson’s disease. For instance, in October 2024, AbbVie Inc., a US-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for VYALEV, a combination therapy containing levodopa and carbidopa, created for the treatment of Parkinson’s disease. Its formulation aims to improve the efficacy of levodopa by inhibiting its breakdown before reaching the brain, thereby increasing dopamine levels. This medication is effective in managing motor symptoms of Parkinson’s disease, including tremors, rigidity, and bradykinesia, which in turn enhances the patient’s ability to carry out daily tasks. It is recognized as a key therapeutic solution for patients with Parkinson’s disease experiencing motor fluctuations.
How do regional factors impact the parkinson’s disease market, and which region is the largest contributor?
North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Parkinson’s Disease Market Report 2025 Offer?
The parkinson’s disease market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Parkinson’s disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing brain cells. It primarily causes tremors, muscle stiffness, slowed movement, and balance difficulties. Treatment often involves medications such as levodopa to alleviate symptoms, complemented by physical therapy and, in certain cases, surgical interventions such as deep brain stimulation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
